Lipocine Inc. Announces Milestone Payment from Abbott Laboratories

SALT LAKE CITY--(BUSINESS WIRE)--Lipocine Inc. (www.lipocine.com) announced today the receipt of a $2 million development milestone payment from Abbott under the terms of its Licensing Agreement to develop and commercialize an oral testosterone product for hypogonadism, also known as low testosterone (low T).

Back to news